<DOC>
	<DOC>NCT02122406</DOC>
	<brief_summary>The primary endpoint of this study is to evaluate the prevalence of anxiety and depressive disorders, and their relationship with disease activity, in patients with rheumatoid arthritis treated with biological drugs</brief_summary>
	<brief_title>Depression and Anxiety in Rheumatoid Arthritis</brief_title>
	<detailed_description>The prevalence of anxiety and depressive disorders will be assesed with the HADS questionnaire at the time of the visit</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>age &gt;18 years diagnosis of rheumatoid arthritis according to 2010 Classification American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Criteria being able to compile questionnaire current treatment with biological diseasemodifying antirheumatic drug Current treatment for anxiety or depressive disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Depression</keyword>
	<keyword>Anxiety</keyword>
	<keyword>DAS28</keyword>
	<keyword>HADS</keyword>
</DOC>